HA
TIL icon

HHLR Advisors’s Instil Bio TIL Stock Holding History

HHLR Advisors’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-119,273
Closed -$25.6M – 71
2022
Q1 		$25.6M Hold
119,273
– – 0.54% 27
2021
Q4 		$40.8M Hold
119,273
– – 0.63% 28
2021
Q3 		$42.6M Hold
119,273
– – 0.56% 27
2021
Q2 		$46.1M Hold
119,273
– – 0.47% 31
2021
Q1 		$59.8M Buy
+119,273
New +$61.2M 0.59% 26

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $14.6M AUM 63.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

HHLR Advisors's TIL Position: Q2 2022 in Review

HHLR Advisors sold out of Instil Bio (TIL) in Q2 2022, closing a stake of 119,273 shares — an estimated $25.6M sold.

HHLR Advisors first reported a position in TIL in Q1 2021 and held it in 5 quarters. The position peaked at $59.8M in Q1 2021. 98 funds tracked by Wall St. Rank hold TIL as of Q2 2022.

  • HHLR Advisors reported no remaining Instil Bio position as of Q2 2022 after selling out during the quarter.
  • HHLR Advisors sold 119,273 Instil Bio shares in Q2 2022, an estimated $25.6M.
  • HHLR Advisors first reported a position in Instil Bio in Q1 2021 and held it in 5 quarters.
  • HHLR Advisors's Instil Bio position peaked at $59.8M in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Instil Bio as of Q2 2022.

Based on HHLR Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.